Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EPIVIR-HBV

« Back to Dashboard

Summary for Tradename: EPIVIR-HBV

Patents:3
Applicants:1
NDAs:2
Suppliers: see list3

Clinical Trials for: EPIVIR-HBV

Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
Status: Completed Condition: Human Immunodeficiency Virus

Pharmacokinetics of Lamivudine at Two Different Doses
Status: Completed Condition: HIV Infections

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load
Status: Active, not recruiting Condition: Hepatitis B, Chronic

Comparison Between Lamivudine and Entecavir Treatment in Patients
Status: Recruiting Condition: Chronic Hepatitis B

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Status: Completed Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir
Status: Completed Condition: HIV

Lamivudine and Adefovir Dipivoxil Fixed Dose Combination
Status: Completed Condition: Hepatitis B, Chronic

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects
Status: Completed Condition: Healthy Volunteers

Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
Status: Recruiting Condition: Chronic Hepatitis B

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
Status: Recruiting Condition: Non-Hodgkin Lymphoma; Hepatitis B Reactivation

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
EPIVIR-HBV
lamivudine
SOLUTION;ORAL021004Dec 8, 1998RXYes6,004,968*PED<disabled>Y<disabled>
Glaxosmithkline
EPIVIR-HBV
lamivudine
TABLET;ORAL021003Dec 8, 1998RXYesRE39155*PED<disabled><disabled>
Glaxosmithkline
EPIVIR-HBV
lamivudine
TABLET;ORAL021003Dec 8, 1998RXYes5,905,082*PED<disabled>Y<disabled>
Glaxosmithkline
EPIVIR-HBV
lamivudine
SOLUTION;ORAL021004Dec 8, 1998RXYesRE39155*PED<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EPIVIR-HBV

Drugname Dosage Strength RLD Submissiondate
lamivudineTablets100 mgEpivir-HBV10/31/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc